中国药物经济学2025，Vol.20Issue(8)：5-12,8.DOI:10.12010/j.issn.1673-5846.2025.08.001
枸橼酸钠血滤置换液用于连续性肾脏替代治疗的成本-效果分析
Cost-effectiveness Analysis of Hemofiltration Replacement Fluid of Sodium Citrate for Continuous Renal Replacement Therapy
谭宝滢 1周柯若 1陈浩锐 1姚强 2祝倾 2白方舟 2王敏敏 2陈楚 2宣建伟1
作者信息
- 1. 中山大学药学院医药经济研究所,广州 510006
- 2. 万益特(中国)投资有限公司,上海 200032
- 折叠
摘要
Abstract
Objective To evaluate the cost-effectiveness of hemofiltration replacement fluid of sodium citrate regimen versus heparin regimen for continuous renal replacement therapy(CRRT)in adult patients.Methods A decision tree model was constructed from the perspective of Chinese healthcare system to assess the health outcomes and costs of hemofiltration replacement fluid of sodium citrate regimen versus heparin regimen in the 28 days of model horizon.Clinical data were gathered from a randomized controlled trial and expert survey in the Chinese context.Cost data were derived from published literature and expert survey.Scenario analysis was conducted based on the use of lactate replacement solution.One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to validate the robustness of the results.Results Base case analysis showed that under the combined use of bicarbonate replacement solution,hemofiltration replacement fluid of sodium citrate regimen avoided 0.01 person-time adverse events compared with heparin regimen and resulting in a total cost savings of 3 784.33 CNY.The results of sensitivity analysis and scenario analysis show that the base case analysis results are relatively robust.Conclusion Compared with heparin regimen,the hemofiltration replacement fluid of sodium citrate regimen is more cost-saving and has a definite advantage for CRRT in adult patients.关键词
枸橼酸钠血滤置换液/肝素/连续性肾脏替代治疗/决策树模型/成本-效果分析Key words
Hemofiltration replacement fluid of sodium citrate/Heparin/Continuous renal replacement therapy/Decision tree model/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
谭宝滢,周柯若,陈浩锐,姚强,祝倾,白方舟,王敏敏,陈楚,宣建伟..枸橼酸钠血滤置换液用于连续性肾脏替代治疗的成本-效果分析[J].中国药物经济学,2025,20(8):5-12,8.
